PsyRx

PsyRx is a pharmaceutical R&D company developing biological API psilocybin and ibogaine in accordance with GMP standards. Using biological bioreactor technology, the company is focused on becoming a leading producer of GMP-standard ibogaine and psilocybin for use by target customers in the development and production of psychedelic- and ibogaine-based pharmaceuticals, food supplements, and other products. PsyRx also aims to develop a revolutionary antidepressant drug based on a combination of ibogaine and existing approved antidepressants, with a focus on reducing side effects and improving efficacy. The companys vision is to develop new drugs for the treatment of depression and addiction by using existing regulatory-approved antidepressant drug formulations with ibogaine. Ibogaine is also known to affect the brain much like antidepressants, but through different pathways. Therefore, PsyRx believes that there might be synergy between these two drugs, enabling them to treat depression with better efficacy and fewer side effects than existing antidepressants.

PsyRx has raised $2.38M in total funding across 3 rounds. The company is currently at the Seed stage.

PsyRx was founded in 2019 by Asher Holzer (Co-founder & Chairman), Itay Hecht (Co-founder & BizDev), Kobi Buxdorf (Co-founder & CTO).

PsyRx operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Herbals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

PsyRx is based in Tel Aviv, Israel, Center District.